Levezil

Levetiracetam, the active ingredient in Levezil, is an anticonvulsant presented as an oral tablet for oral use. It is prescribed to manage partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy, offering a broad spectrum of seizure control across adult and pediatric populations.

GNH USA supplies Levezil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global logistics for regulated medicines, with dedicated regulatory support and on‑time delivery.

Levezil is used to treat seizure disorders within the epileptic disease spectrum.

Partial seizures: reduces frequency of focal onset seizures, improving seizure control. Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. Myoclonic seizures: diminishes rapid jerking movements associated with myoclonic epilepsy.

Levezil may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome or other severe skin reactions - Blood dyscrasias such as agranulocytosis - Suicidal ideation or severe depression - Rash with mucosal involvement

When prescribing Levezil, clinicians should consider several safety measures.

Dose adjustment: required in patients with renal impairment according to creatinine clearance. Pregnancy: safety not established; use only if benefits outweigh risks. Concomitant CNS depressants: monitor for additive sedation. Behavioral changes: observe for mood swings, aggression, or depression. Avoid abrupt discontinuation: taper under medical supervision to reduce seizure recurrence. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Levezil can interact with other medicines, necessitating careful review.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, reducing levetiracetam levels. - Phenobarbital: enzyme induction may lower efficacy. - Phenytoin: may decrease plasma concentrations of levetiracetam.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression. - Other antiepileptics (e.g., valproate): may require dose adjustment. - Renal excretion inhibitors (e.g., probenecid): may increase levetiracetam exposure.